Who are peers of Dishman Carbogen Amcis Ltd? The peers of Dishman Carbogen Amcis Ltd are Sun Pharmaceuticals Industries ... fall ‘$21M for voter turnout in India’: Elon Musk’s DOGE cuts ...

Feb 14 (Reuters) - India's Glenmark Pharmaceuticals (GLEN.NS), opens new tab reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

India and Myanmar on, February 14, discussed possibilities in areas of pharmaceuticals, pulses & beans, petroleum products and greater use of the recently launched Rupee-Kyat Trade Settlement ...

NBCC India, on the other hand, has seen its shares falling in five of last six sessions. Analysts noted Natco Pharma’s missed Q3 consensus estimates on both revenue and Ebitda margin fronts.

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

Dishman Carbogen Amcis Ltd., incorporated in the year 2007, is a Small Cap company (having a market cap of Rs 3,183.17 Crore) operating in Pharmaceuticals sector. Dishman Carbogen Amcis Ltd. key ...

They have two manufacturing units in India, located at Nashik and Thane. Also, they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 ...

The main objects of the company is to carry on business in chemicals,fine chemicals, drug intermediates, Solvents, drugs,pharmaceuticals ... 2004 -Alpha Drug India Ltd has informed that the ...

Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is ...

“The pharmaceutical industry is globalized: generic drugs manufactured at sites in India will be produced using imported materials and be shipped to distributors worldwide, who will coordinate ...

The pharmaceutical industry is at a pivotal moment. Artificial intelligence (AI) is shifting from improving processes to reshaping disease treatment and care delivery. Early adopters are seeing ...